KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Model-informed drug development in public health emergency of international concern: accelerating marketing authorization of simnotrelvir.

Bu-Fan Yao, Yang Yang, Shan-Sen Xu, Bo-Hao Tang, Jia Chen, Zi-Jia Guo, Hong-Lin Hu, Wei Zhang, Shu-Meng Fu, Xin-Fang Zhang, Guo-Xiang Hao, Xin-Mei Yang, Lin-Lin Song, Pan-Pan Ye, Lian Liu, Shun-Wei Zhu, Yi Zheng, Wei Zhao

Antimicrob Agents Chemother 69(11) e0061425

PMID40965470
PMCIDPMC12587539
DOI10.1128/aac.00614-25
发表日期2025-09-18
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig 1:AI 判定为 other;Fig 2:AI 判定为 other;Fig 3:AI 判定为 other;Fig 4:AI 判定为 other。
摘要

摘要

During a Public Health Emergency of International Concern (PHEIC), rapid drug development is critical, but traditional clinical trials are time-consuming and high-risk. This study used coronavirus disease 2019 (COVID-19) as an example to highlight the pivotal role of model-informed drug development (MIDD) in expediting the marketing authorization of simnotrelvir in China, a 3CLpro inhibitor for COVID-19 treatment. Three simnotrelvir clinical trials (Phase Ia, Ib, II/III) were optimized using the MIDD approach. Pharmacokinetics was investigated using nonlinear mixed-effects models, exposure was calculated through Monte Carlo simulation and Bayes estimation, and exposure-efficacy/safety relationships were analyzed using linear/logistic regression models. The MIDD approach began with a translational study to predict patients' starting doses using first-in-human data, preclinical data, and pharmacodynamic surrogate marker. A dose level of 750 mg/100 mg simnotrelvir/ritonavir was recommended, using simulation results with 90.6% of participants' trough concentration exceeding EC90 for anti-Omicron variant. Then, a biomarker confirmation study to investigate dose-exposure-response relationship found that 750 mg suppressed viral load more than 300 mg (-4.995 vs. -4.236 log10 copies/mL, P = 0.0367) in Phase Ib. Finally, a randomized controlled trial to confirm benefit-risk ratio found that simnotrelvir/ritonavir reduced time to sustained resolution of 11 clinical syndromes by 1.5 days compared with placebo, had no serious adverse events, and had a flat exposure-response relationship with viral load reduction, time to sustained resolution, and ≥2 grade treatment-emergent adverse event rate with approved dosage. MIDD enhanced clinical trial success, optimized the benefit-risk profile, and expedited marketing authorization for new drug development in response to PHEIC.CLINICAL TRIALSThis study is registered with ClinicalTrials.gov as NCT05339646, NCT05369676, and NCT05506176.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig 1Fig 1 The concentration versus time curve of simnotrelvir from first-in-human trial used in model 1. ( A ) Simnotrelvir monotherapy in Phase Ia single-ascending dose part; ( B ) simnotrelvir monotherapy in Phase Ia multiple-ascending dose part; ( C ) simnotrelvir/ritonavir in Phase Ia single-ascending dose part and food effect part; ( D ) simnotrelvir/ritonavir in Phase Ia multiple-ascending dose part.
非 KM Figure
Fig 2Fig 2 Goodness of fit plots of final simnotrelvir model 1. ( A ) Observed concentration versus individual predicted concentration; ( B ) observed concentration versus population predicted concentration; ( C ) conditional weighted residuals versus population predicted concentration; ( D ) conditional weighted residuals versus time. The red line represented a locally estimated scatterplot smoothing (LOESS) curve, which helped to identify systematic trends or biases between observed data and model predictions. In Fig. 2C and D, the dashed horizontal lines at CWRES = ±2 represented the ±2 standard deviation boundaries. The fact that the vast majority of CWRES values (over 95%) fall within this range supported the assumption of normally distributed residuals and indicated that the model adequately characterized random variability.
非 KM Figure
Fig 3Fig 3 The viral load reduction of different groups in the Phase Ib clinical trial. The viral load reduction data of every group was shown as average and standard deviation (SD).
非 KM Figure
Fig 4Fig 4 The relationships between efficacy or safety endpoints and simnotrelvir exposure in Phase II/III trials. Efficacy endpoints: ( A ) viral load reduction vs C trough ; ( B ) time to sustained resolution vs. C trough . Safety endpoints: ( C ) grade 2 or higher treatment-emergent adverse event (≥2 grade TEAE) rate vs C max ; ( D ) ≥ 2 grade TEAE rate vs AUC; ( E ) triglyceride change from baseline vs C max ; ( F ) triglyceride change from baseline vs. AUC. The fractions in Fig. 4C and D represent the observed number of participants with grade ≥2 TEAEs over the total number of participants within each C max or AUC quartile group.
非 KM Figure